ABL Bio, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 102
- Market Cap
- -
- Website
- http://www.ablbio.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT07158918
- Locations
- 🇺🇸
UH Cleveland Medical Center, Cleveland, Ohio, United States
🇦🇺PASO Medical, Frankston, Victoria, Australia
🇰🇷Seoul National University Bundang Hospital, Seongnam, South Korea
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06126666
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Seoul, South Korea
🇰🇷Seoul National University Hospital, Seoul, Seoul, South Korea
🇰🇷Sevrance Hospital, Seoul, South Korea, South Korea
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT05756920
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05101109
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04762641
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸USC, LA, California, United States
🇺🇸UCLA, Santa Monica, California, United States
- Prev
- 1
- 2
- Next